Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Depreciation & Amortization (CF) (2016 - 2026)

Neurocrine Biosciences filings provide 16 years of Depreciation & Amortization (CF) readings, the most recent being $6.4 million for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 3.23% to $6.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $26.0 million, a 10.64% increase, with the full-year FY2025 number at $26.0 million, up 10.64% from a year prior.
  • Depreciation & Amortization (CF) hit $6.4 million in Q4 2025 for Neurocrine Biosciences, down from $6.7 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $6.7 million in Q3 2025 to a low of $2.5 million in Q1 2021.
  • Median Depreciation & Amortization (CF) over the past 5 years was $4.4 million (2023), compared with a mean of $4.7 million.
  • Biggest five-year swings in Depreciation & Amortization (CF): soared 52.38% in 2024 and later fell 1.56% in 2025.
  • Neurocrine Biosciences' Depreciation & Amortization (CF) stood at $3.0 million in 2021, then grew by 30.0% to $3.9 million in 2022, then grew by 25.64% to $4.9 million in 2023, then grew by 26.53% to $6.2 million in 2024, then grew by 3.23% to $6.4 million in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $6.4 million (Q4 2025), $6.7 million (Q3 2025), and $6.3 million (Q2 2025) per Business Quant data.